Nautilus Biotechnolgy, Inc. (NAUT) Stock Grade

About Nautilus Biotechnolgy, Inc.'s fundamentals

Nautilus Biotechnology is a small-cap biotech company with a market capitalization of $246.2 million that reported zero year-over-year revenue growth and posted a net loss in its latest annual statement, resulting in a net margin of 0.0%. The company does not currently pay a dividend, and profitability metrics like P/E ratio and return on equity are not applicable given the loss position. As a pre-revenue or early-stage biotech firm, the company's financial performance reflects the typical cash-burn pattern common to development-stage biotechnology companies.